CPD accredited On Demand Webinars

NOFSA 2023 Masterclass series

Held on 14 March 2023

1. A long-term personalised osteoporosis management plan is necessary prior to initiating therapy

Chronic illness and Ramadan fasting – Optimal management for patients intending to fast

Held on 07 February 2023, with an unrestricted co partnership from Eli Lilly and Sanofi

Ramadan fasting can be challenging for Muslim patients with chronic conditions like type 2 diabetes. In this report, two experts offer guidance on how these individuals can minimise their risk and fast safely during this time.

Ixekizumab and newer therapies for plaque psoriasis

Held on 30 January 2023, with an unrestricted partnership from Eli Lilly 

Psoriasis severely impacts patients’ quality of life. This review explains this impact and evaluates the encouraging clinical data on ixekizumab, a new biologic therapy that is achieving unprecedented positive outcomes in these patients.

Baricitinib therapy in Rheumatoid arthritis

Held on 25 January 2023, with an unrestricted partnership from Eli Lilly

The Janus kinase inhibitor, baricitinib, is showing considerable benefit in rheumatoid arthritis patients who don’t respond to established therapies. In this review, an expert discusses the evidence for its safety and efficacy.

Challenges in the management of geriatric oncology patients

Held on 28 November 2022, with an unrestricted partnership from Eli Lilly

The management of geriatric oncology patients poses a number of challenges to clinicians

Inflammatory arthritis – Treatment approaches in the era of biologics

Held on 30 November 2022, with an unrestricted partnership from Eli Lilly

Managing inflammatory arthritis – goals of treatment and the utility of biologics in achieving these

Time in range – What is it, and does it matter?

Held on 24 November 2022, with an unrestricted partnership from Eli Lilly

Long-term clinical outcomes in both type 1 and type 2 diabetes are associated with time in range at baseline

Ethics and vulnerability

Held on 23 November 2022, with an educational grant from Cipla

Expanding on HPCSA guidance with specific case studies highlighting competing rights, the autonomy of patients and the ability/competency of patients to exercise their rights

Ethical sharing of patient information

Held on 24 August 2022, with an educational grant from Cipla

Making the right decision about sharing your patients information

The complex interplay between COVID-19 and diabetes

Held on 26 July 2022, with an unrestricted partnership from Eli Lilly

Diabetes patients are particularly at risk of hyperinflammation

Practical considerations in cancer-associated thrombosis

Held on 1 June 2022, with an unrestricted educational grant from Bayer

The risk of venous thromboembolism recurrence changes in the cancer patient over time

Management of hospitalised severe COVID-19 patients

Held on 31 May 2022, with an unrestricted partnership from Eli Lilly

Best-practice management of hospitalised, severe COVID-19 patients requiring oxygen therapy

Missed opportunities when treating hypertension

Held on 17 May 2021, with educational grant from Servier

Note potential barriers to adherence to assist the patient with persistence and long-term BP control

Patient autonomy and balancing the rights of patient, community and healthcare workers

Held on 11 May 2022, with an educational grant from Cipla

Do good, avoid harm and advise actions that are fair and equitable

JAK (Janus kinase) inhibitors in rheumatoid arthritis

Held on 29 March 2022, with an unrestricted sponsorship from Eli Lilly

Novel oral RA medication, JAK inhibitors, have shown superiority to treatment and pain relief

NOFSA 2022 Masterclass series

Held on 9 March, 10 May 2022, 14 June, 19 July and 10 August

1. A practical approach to the management of osteoporosis
2. Managing the elderly patient with osteoporosis and fractures
3. The essentials of DXA interpretation in osteoporosis management 
4. Medicines and Osteoporosis: a focus on concerning effects of anti-osteoporotic and other medications
5. Patients with low bone mass – What is going on?

Diabetes and Ramadan – fasting diabetic patients

Held on 8 March 2022, with an unrestricted sponsorship from Eli Lilly

Guidance on how to prepare your insulin dependent Diabetic patient who wants to fast during Ramadan

Long COVID and mental health – the new clinical challenge

Held on 23 February 2022, with an educational grant from Cipla

Heightened fear, anxiety and depression in patients diagnosed with COVID-19 is affecting their mental health.

Diabetes and Ramadan – practical insulin management

Held on 22 February 2022, with an unrestricted sponsorship from Eli Lilly

Insulin treatment regimens of diabetic Muslims need modification of timing and/or dosage during Ramadan.

Scottsdale Headache Symposium 2021 – Migraine and Headaches

Held on 8 December 2021, with an unrestricted sponsorship from Eli Lilly

Treating patients with chronic migraines can be a headache – the goal is to achieve rapid consistent freedom from pain and other symptoms.

Multiple sclerosis in primary care – diagnosis and early treatment

Held on 10 November 2021, with an unrestricted educational grant from Merck

A specialist neurologist outlines clinical features and diagnostic criteria, and offers guidance on optimal current treatments in this CPD-accredited report.

Cancer webinar series 2021

Held on 9 and 15 Dec 2020 and 20 Jan 2021with educational grant from AstraZenca

Spotting the warning signs of cancer – WHICH patients are at high risk, WHAT investigations to do at Primary Care level and WHEN to refer?

Anti-VEGF Agents – The Importance of Early Switching when Treatment Fails

Held on 3 November 2021, with an unrestricted educational grant from Bayer

Intravitreal anti-VEGF therapy is used in the treatment and management of sight threatening DME and nAMD

Angina: A missed medical opportunity

Held on 18 March 2021, with educational grant from Servier

Best initial management of stable angina starts with correct assessment; lifestyle management, anti-ischaemic drugs and prevention of adverse CV events are key, the role of revascularisation is now confined to specific subgroups.

Heart Failure – New Guidelines, New Treatments

Held on 6 October 2021, with an unrestricted educational grant from Boehringer Ingelheim, Bayer and Biotronik

Learn more about the latest treatments for heart failure in this CPD-accredited report by a leading South African expert.

A new decade for patients with atrial fibrillation

Held on 29 March 2021, with educational grant from Bayer

Post-COVID-19 investigations of the atrial fibrillation patient should include an ECG and cardiac MRI scan to determine the presence of COVID-19 myocarditis.

Clinical update: Colorectal, head and neck cancers

Held on 31 August 2021, with educational grant from Merck

In a comprehensive review of colorectal cancers and those of the head and neck, an expert oncologist considers the signs and symptoms of each

Treating your virtual patient – What are your ethical and legal responsibilities

Held on 21 April 2021, with educational grant from Cipla

The COVID-19 pandemic has accelerated the adoption of telehealth in routine clinical practice. Learn more about the guidelines, regulations and inadequacies of telehealth in this CPD accredited report.

Reshaping Rheumatology – The era of biosimilars

Held on 19 June 2021, with educational grant from Cipla

In this CPD-accredited report, Professor Peter Nash of Griffith University, Australia, discusses perceptions and misconceptions with regard to biosimilars as therapy for rheumatological disease.

The POPIA is here! What now?

Held on 21 of July 2021, with educational grant from Cipla

The Protection of Personal Information Act is here at last and took effect on 1 July 2021. In this overview, an attorney considers the Act in the context of healthcare practice management.

Heart failure update

Held on 8 October 2020 from the MERCK Medical summit 2020, with educational grant from Merck

Investigating heart failure? Recognise typical symptoms and learn about classification criteria, the importance of heart rate in the development of heart failure and the role of beta blockers and other therapies in treatment.